BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD).

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a clinical collaboration agreement with Novartis to evaluate OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in combination with each of Kisqali®

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that it completed enrollment in its Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced today that members of management will participate in a Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 2:00 p.m. ET.

BioSkryb, Inc., a developer of genomic amplification technologies, today announced the commercial launch of ResolveDNATM products to accurately and uniformly reproduce genomes of single cells.

- OneOncology, the national partnership of independent oncology practices, today announced that Bob Gallagher has been appointed Chief Operations Officer overseeing all operations functions for the high-growth community-based oncology platform. Before coming to OneOncology, Gallagher was a division vice president at DaVita, a nat

ISOThrive Inc. has been awarded $800,000 from Virginia Catalyst to advance its microbiome therapeutic for Gastroesophageal Reflux Disease (GERD).

Despite the COVID-19 pandemic – and with more than two months remaining in 2020 – a record number of Hoosier organ donors have already given the gift of life through Indiana Donor Network, resulting in a record number of lifesaving organs transplanted in a single calendar year.

BioCanna Health Care Inc., a leading innovator in pharmaceutical applications of Cannabinoids, Terpenes and other biomaterials, has announced that its wholly owned subsidiary, BioCanna CuraLab, in collaboration with University of Ottawa , has made a breakthrough development in its “BioNano Virus Detection System” by innovative a